Falling Covid-19 infection numbers in Pakistan will not affect a Phase 3 clinical trial for a potential vaccine being developed by China's CanSino Biologics , which is expected to begin this month, according to officials running the trial.
“We are planning to launch the project on September 20, or at the latest within this month,” Hassan Abbas Zaheer, who is heading the trial for AJM, told Reuters.
Read the full story here.
